MedPath
EMA Product

Levitra

Product approved by European Medicines Agency (EU)

Basic Information

Levitra

Regulatory Information

EMEA/H/C/000475

Authorised

March 6, 2003

34

December 4, 2023

Company Information

Germany

Bayer AG 51368 Leverkusen

BAYER AG

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Treatment of erectile dysfunction in adult men. Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for Levitra to be effective, sexual stimulation is required. Levitra is not indicated for use by women.

Overview Summary

This is a summary of the European public assessment report (EPAR) for Levitra. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levitra.

© Copyright 2025. All Rights Reserved by MedPath